REG - BioPharma Credit PLC - STATEMENT RE IMMUNOCORE HOLDINGS PLC

Biopharma CreditAnnouncement

12/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241112:nRSL7938La&default-theme=true

RNS Number : 7938L  BioPharma Credit PLC  12 November 2024

BioPharma Credit PLC

12 November 2024

 

 

 

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

STATEMENT RE Immunocore Holdings plc

 

Pharmakon Advisors, LP, the investment manager of the Company, notes the
announcement released 8 November 2024 by Immunocore Holdings plc
("Immunocore") regarding the prepayment in full of the US$50 million senior
secured term loan, of which the Company had an investment of US$25 million.
The prepayment included a US$1.5 million prepayment fee, of which the Company
received US$750,000.

 

The Company had previously announced on 21 November 2022 an investment in a
senior secured loan to Immunocore of up to US$100 million in up to two
tranches. The Company had previously funded US$25 million and Immunocore did
not draw the second tranche. In connection with this final repayment, the
Company received US$1,014,063 of accrued interest and prepayment fees.

 

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRDGBDBUSBDGSB